

Date: August 14, 2025

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
Mumbai 400001
Script Code: 540359

Dear Sir,

SUB: OUTCOME OF BOARD MEETING HELD ON AUGUST 14, 2025 AND SUBMISSION OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30, 2025 PURSUANT TO PROVISIONS OF REGULATIONS 30 AND 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

With reference to the above subject, we would like to inform you that Board of Directors of Atul Auto Limited at its meeting held today i.e. Friday, August 14, 2025 inter-alia decided as under:

1. Considered and approved unaudited standalone financial results of the company for the quarter ended June 30, 2025.
2. Appointment Mr. Samsad Alam Khan (Membership No. F13629, CP No. 13972), Practicing Company Secretaries, Ahmedabad as Secretarial Auditors to conduct the secretarial audit of the Company for a first term of five consecutive years from FY 2025-26 to FY 2029-30 subject to approval of shareholders in ensuing AGM.

The details as required in terms of Regulation 30 read with Part-A of Schedule III of the SEBI LODR and SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure-A.

In this respect, we are attaching herewith following documents:

1. Unaudited Standalone Financial Results for the quarter ended on June 30, 2025.
2. Limited Review Report of the Statutory Auditors of the Company i.e. M/s. B A Shah S R Mehta & Co. on the above Result.

The meeting of Board of Directors commenced at 12:15 PM IST and ended at 14:35 PM IST.
Thanking you.

Yours faithfully,

For, Parmax Pharma Limited

Digitally signed by
UMANG ALKESH
Date: 2025.08.14 14:49:44
+05'30'
UMANG ALKESH GOSALIA
GOSALIA

**Umang Alkesh Gosalia
Managing Director**

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 **Fax :** +91-2827-270536 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

Sr. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Secretarial Auditor
2	Date of appointment/ ~~cessation~~ (as applicable) & term of appointment;	Date of appointment: August 14, 2025 Appointment of Secretarial Auditors to conduct the secretarial audit of the Company for a term of five years from financial year 2025-26 to FY 2029-30 subject to approval of shareholders in ensuing AGM.
3	Brief profile (in case of appointment)	Mr. Samsad Alam Khan is a peer-reviewed Practicing Company Secretaries, registered with the Institute of Company Secretaries of India (ICSI). He brings over 13 years of professional experience in Company Law, SEBI (LODR) Regulations, RBI FEMA Compliances and Intellectual Property Rights (IPR). It caters to a diverse clientele across various corporate sectors, offering comprehensive and compliant solutions.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Statement of Standalone Audited Results for the Quarter ended 30.06.2025					
		Quarter Ended 30.06.2025	Preceding Quarter Ended 31.03.2025	Corresponding Quarter Ended 30.06.2024	(In Rs. Thousands) Previous Year Ended 31.03.2025
	(Refer Notes Below)	(Un Audited)	(Audited)	(Un Audited)	(Audited)
I.	Revenue from operations	19423.11	48257.28	78163.00	282039.58
II.	Other income	66.85	-976.63	80.14	395.78
III.	Total Income (I+II)	19489.96	47280.65	78243.14	282435.36
IV.	Expenses				
	(a) Cost of materials consumed	8496.81	29611.25	61739.05	215379.62
	(b) Purchase of stock-in-trade	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1226.39	7482.43	-3085.71	-25.00
	(d) Employee benefits expense	6315.11	5748.55	7484.86	29883.40
	(e) Finance Costs	2801.02	2376.68	1126.16	5855.39
	(f) Depreciation and amortisation expense	2412.42	-1769.57	3962.24	10316.94
	(g) Other expenses	5883.19	11071.15	6893.34	34256.42
V	Total expenses (IV)	27134.94	54520.49	78119.94	295666.77
	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-7644.98	-7239.84	123.20	-13231.41
VI	Exceptional Items	.00	10719.64	0	10719.64
VII	Profit/ (Loss) before tax (V-VI)	-7644.98	-17959.48	123.20	-23951.05
VIII	Tax expense:				
	(1) Current tax	0	0	0	0
	(2) Deferred tax	0	-3010.96	0	-3010.96
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-7644.98	-14948.52	123.20	-20940.10
X	Profit/(loss) from discontinued operations				
XI	Tax expense of discontinued operations	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0
XIII	Profit (Loss) for the period (IX+XII)	-7644.98	-14948.52	123.20	-20940.10
	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss				
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XIV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-7644.98	-14948.52	123.20	-20940.10
XV	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000
XVI	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each) :				
	(a) Basic	-2.04	-4.00	0.03	-5.60
	(b) Diluted	0.00	0.00	0.00	0.00

Notes:

1. The above-unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th August 2025
2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2025
3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
4. The figures for the previous period have been re-grouped wherever necessary.

FOR, PARMAX PHARMA LIMITED

UMANG
ALKESH
GOSALIA

Digitally signed by
UMANG ALKESH
GOSALIA
Date: 2025.08.14
14:46:43 +05'30'

Place Hadamtala (Rajkot)
Date: 14.08.2025

Umang Alkesh Gosalia
Managing Director

B A SHAH S R MEHTA & CO.

Chartered Accountants

Partner
Malay B Shah
B.Com., F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com., F.C.A., DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

The Board of Directors,

PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended **30th June 2025** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14th August, 2025**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr. Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149

(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com

B A SHAH S R MEHTA & CO.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA
(Information Systems Audit)

M. No. 144246

Company is awaiting Surveyors Report for fire took place in the month of Dec 2023, in absence of Surveyors Report Claim of Rs. 350 Lacs is not yet submitted with Insurance company.

Company has not provided depreciation on clean room plant and effluent treatment plant considering non usage of these assets.

Based on our review conducted except as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot

Date: 14.08.2025

For **B. A. SHAH S R MEHTA & Co.**

Chartered Accountants

FRN NO: 128796W



MALAY B SHAH

Partner

M. No. 159526

UDIN: 25159526BMNY005970

Head Office:

209-Sapphire Complex, 11th Floor

21/25-B New Jagnath Plot,

Dr. Yagnik Road

RAJKOT- 360 001

(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149

(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com